Cellular immune responses in transplantation-associated chronic viral infections

Transplant Infectious Disease

Volumn 4, Issue 1, 2002, Pages 31-40

  Addo, M M ^a,b   Rosenberg, E S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Epstein Barr virus; Humoral and cellular immunity; Immune evasion; Immunotherapy; Opportunistic infection

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; DRUG MECHANISM; DRUG POTENTIATION; EPSTEIN BARR VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TRANSPLANTATION; VIRUS IMMUNITY; VIRUS INFECTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION;

EID: 0036078547     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2002.00006.x     Document Type: Article

References (96)

1. Antiviral protection by virus-immune cytotoxic T cells: Infected target cells are lysed before infectious virus progeny is assembled
2. Mechanisms of MHC class I-restricted antigen processing
3. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
4. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
5. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
6. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
7. Viral immune evasion due to persistence of activated T cells without effector function
8. Cytomegalovirus seroprevalence in women bearing children in Jefferson County
9. Cytomegalovirus infection following stem cell transplantation
10. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
11. Interactions of cytomegalovirus with the human immune system
12. Interstitial murine cytomegalovirus pneumonia after irradiation: Characterization of cells that limit viral replication during established infection of the lungs
13. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity
14. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
15. Antiviral immunity
16. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients
17. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defence mechanism in cytomegalovirus infections
18. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
19. Recovery of HLA-restricted cytomegalovirus-specific T-cell responses after allogeneic bone marrow transplant: Correlation with cytomegalovirus disease and effect of ganciclovir prophylaxis
20. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
21. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load
22. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
23. Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients
24. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants
25. Quantification of cytotoxic T-cell gene transcripts in human lung transplantation
26. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation
27. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
28. Negative result of cytomegalovirus blood culture with restoration of CD4+ T-cell reactivity to cytomegalovirus after HAART in an HIV-1-infected patient
29. Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B
30. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB. 150, and pp28 in healthy individuals: Re-evaluation of prevalence of IE1-specific CTLs
31. Viral strategies of immune evasion
32. Human cytomegalovirus replication and modulation of apoptosis in astrocytes
33. Decreased cytomegalovirus expression following proinflammatory cytokine treatment of primary human astrocytes
34. Cytomegalovirus infection of peripheral blood mononuclear cells. Effects on interleukin-1 and 2 production and responsiveness
35. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus
36. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains
37. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains
38. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process
39. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction
40. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol
41. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells
42. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo
43. Inhibition of NK cells by murine CMV-encoded class I MHC homologue m144
44. Impacts of cytomegalovirus infection on organ transplant recipients
45. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial
46. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients
47. Vaccines for the prevention of human cytomegalovirus infection
48. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin
49. Cytomegalovirus vaccine
50. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
51. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients
52. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease
53. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection
54. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients
55. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection
56. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors
57. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence
58. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
59. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
60. Deficient cellular immunity finding and fixing the defects
61. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
62. Post-transplant lymphoproliferative disorders: A morphologic, phenotypic and genotypic spectrum of disease
63. Epstein-Barr virus lymphoproliferation after bone marrow transplantation
64. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children
65. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
66. Infections in solid-organ transplant recipients
67. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
68. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection
69. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
70. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
71. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
72. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis
73. A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection
74. Herpes virus evasion of the immune system
75. EBV persistence in memory B cells in vivo
76. Suppression of c-Myc-induced apoptosis by the Epstein-Barr virus gene product BHRF1
77. The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type
78. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness
79. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells
80. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
81. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: Evidence for immune pressure-independent genetic drift
82. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
83. Donor T cells to treat EBV-associated lymphoma
84. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
85. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
86. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post transplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
87. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
88. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype
89. Mig., the monokine induced by interferon-gamma, promotes tumor necrosis in vivo
90. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
91. A phase I-II trial to examine the toxicity of CMV and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants
92. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
93. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis
94. Active immunization of humans with dendritic cells
95. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
96. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses